Revealed: the undisclosed safety data emerging as weedkiller maker faces Parkinson’s lawsuits in US

Syngenta is under pressure as undisclosed safety data on paraquat, a weedkiller linked to Parkinson's disease, emerges amid multiple lawsuits in the US. The company denies withholding relevant information from the EPA, yet the evidence of regulatory action elsewhere tells a different story. Sweden banned paraquat in 2004; dozens of countries followed suit over two decades. China – which owns Syngenta – halted domestic use a decade ago after its own safety studies raised concerns. Vermont and California have recently implemented state-level bans, citing Parkinson's risk established through years of peer-reviewed research. California regulators announced in August that paraquat makers had agreed voluntarily to stop selling the product following new health assessments. Several federal lawmakers are pushing for a nationwide US ban.

The pattern is stark: a chemical phased out globally by governments and its own parent shareholder, yet still legal and marketed in the US market. This raises direct questions about regulatory capture, data transparency, and corporate accountability. If the health evidence was sufficient to prompt China's own government to withdraw the product domestically, the claim that US regulators lack material information strains credibility. The case exposes how divergent regulatory frameworks allow hazardous substances to persist in some markets whilst banned elsewhere – a classic arbitrage of risk that shifts liability and health burden to populations in deregulated jurisdictions.

For ESG investors and procurement teams, this matters. It signals potential governance failures at Syngenta and raises materiality questions about chemical safety disclosure, supply-chain risk management, and alignment with parent-company risk appetite. The lawsuits themselves represent financial, reputational, and legal exposure that should flag in due diligence.